Category: eClinical Systems
Building and validating the data-capture database for a new trial takes weeks of specification, configuration, and testing — and enrollment can't start without it.
Before a trial can enroll its first patient, the study database has to exist: every form, field, edit check, and integration specified, configured, and tested against the protocol. That build-and-validate cycle routinely sits on the critical path to study start, and every protocol quirk adds specification rounds between data management, clinical, and programming teams. AI-assisted study-build tools draft database configurations from the protocol and an organization's standards library, so data managers start from a reviewed draft instead of a blank specification.
Study-build tools work from the documents a build already depends on: the protocol's schedule of assessments and the organization's library of standard forms and edit checks. Language-processing capabilities read the protocol, match its assessments to existing standards, and draft the corresponding forms, visit structures, and validation rules — flagging where the protocol needs something the library doesn't have. Reuse is the other lever: most new studies overlap heavily with prior ones, and tooling that finds and adapts the closest prior build turns configuration into review. The draft is a starting point, not a finished database. Data managers review every form and check, user acceptance testing still happens, and the accountable build decisions — what to collect, how to validate it — stay with the data-management team. The gain is in removing transcription between protocol and specification, so expert time goes to the judgment calls rather than re-keying structure that already exists elsewhere.
Draft quality on your own protocols is the deciding test: ask a vendor to generate a build draft from a real (appropriately controlled) protocol against your standards library, and have your data managers score how much of it survives review. Probe what happens when the protocol is ambiguous or novel — a credible tool flags gaps for a human decision rather than inventing a plausible form. Compatibility matters just as much: the output has to land in your actual data-capture platform, in a format your team can refine, not a parallel system that creates its own migration problem. Because the study database is a validated system, examine how drafted configurations enter your existing validation and change-control process, how versions and review sign-offs are captured, and what documentation the tool produces to support that process rather than bypass it.
A low-risk pilot runs the tool in parallel on a real upcoming study: generate the draft build from the protocol while the team builds as usual, then compare the draft against the final validated database. That measures how much of the build the tool got right, where it erred, and how much calendar time it could have removed — all without putting a live study on an unproven path. Teams that see strong drafts typically adopt the tool for the first-draft stage while keeping their existing review and validation gates unchanged.
It reads the protocol and drafts the database configuration — forms, visit structure, edit checks — from your standards library and closest prior studies, so data managers review and refine a draft instead of specifying from scratch. The build decisions and validation testing remain with the data-management team.
No. The study database is a validated system, and user acceptance testing, review sign-offs, and change control apply regardless of how the first draft was produced. Credible tools are built to feed your validation process with documentation, not to bypass it.
That is one of the first things to verify. The draft has to land in the platform your sites and data managers actually use, in a form your team can refine. A tool that produces output your platform can't ingest just moves the transcription work rather than removing it.
Ask them to draft from one of your real protocols against your standards library, show how the output enters your platform and validation workflow, demonstrate what happens when the protocol is ambiguous or novel, and quantify — on your own study — how much of the draft survived expert review.
Syntegra partnered with Datavant to connect its synthetic data engine with Datavant's de-identification and record-linking network, enabling privacy-preserving exchange of synthetic versions of linked real-world health datasets across the healthcare ecosystem.
Vendor: Syntegra · press release (Syntegra (GlobeNewswire)) · 2022-12-15 — Partner: Datavant
Abridge was named the first member of Epic's 'Pals' partnership program, integrating its generative-AI medical conversation summaries directly into Epic EHR workflows so health systems can adopt ambient documentation inside the tools clinicians already use.
Vendor: Abridge · press release (Abridge) · 2023-08-16 — Partner: Epic
Saama's AI-driven clinical analytics supported Pfizer's review of clinical trial data during its COVID-19 vaccine program; the companies subsequently expanded their relationship across Pfizer's broader R&D data operations.
Vendor: Saama Technologies · press release (Saama (Business Wire)) · 2024-02-12 — Partner: Pfizer
Kaiser Permanente rolled out Abridge's ambient AI clinical documentation technology across its integrated health system — 40 hospitals and more than 600 medical offices — letting clinicians generate draft visit notes from patient conversations instead of typing during encounters.
Vendor: Abridge · press release (Kaiser Permanente) · 2024-08-14 — Partner: Kaiser Permanente
A quality-improvement survey at the University of Kansas Medical Center, published in JAMIA Open, reported that clinicians using Abridge's ambient AI documentation self-reported lower perceived work burden and burnout and higher job satisfaction after implementation. Vendor-affiliated authors participated in the study.
Vendor: Abridge · peer reviewed (JAMIA Open (Oxford University Press)) · 2025-02-21